Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis

Clinical Therapeutics

Volumn 28, Issue 12, 2006, Pages 1972-1982

  Hebert, Adelaide A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

atopic dermatitis, pimecrolimus, topical calcineurin inhibitor, topical corticosteroids

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; DESONIDE; DESOXIMETASONE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUTICASONE PROPIONATE; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE VALERATE; MOMETASONE FUROATE; PIMECROLIMUS; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE;

APPLICATION SITE REACTION; ATOPIC DERMATITIS; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; BRONCHITIS; BURNING SENSATION; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; CREAM; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EMBASE; HERPES SIMPLEX; HUMAN; INFLUENZA; MEDLINE; PHOTOTHERAPY; REVIEW; RHINOPHARYNGITIS; SCISEARCH; TREATMENT INDICATION; VIRAL SKIN DISEASE; VIRUS INFECTION;

ADMINISTRATION, CUTANEOUS; CLINICAL TRIALS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; OINTMENTS; TACROLIMUS;

EID: 33846840779     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.12.014     Document Type: Review

References (44)

1. Elidel [prescribing information] (2006), Novartis Pharmaceuticals Corporation, East Hanover, NJ
2. Diepgen T.L. Is the prevalence of atopic dermatitis increasing?. In: Williams H.C. (Ed). Atopic Dermatitis: The Epidemiology, Causes and Prevention ofAtopic Eczema (2000), Cambridge University Press, New York, NY 96-109
3. Leung D.Y., Boguniewicz M., Howell M.D., et al. New insights into atopic dermatitis. J Clin Invest 113 (2004) 651-657
4. Beltrani V.S., and Boguniewicz M. Atopic dermatitis. Dermatol Online J 9 (2003) 1
5. Rajka G. Clinical aspects. In: Rajka G. (Ed). Essential Aspects of Atopic Dermatitis (1989), Springer-Verlag, Berlin, Germany 4-55
6. Wuthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol 83 (1999) 464-470
7. Williams H.C., and Strachan D.P. The natural history of childhood eczema: Observations from the British 1958 birth cohort study. Br J Dermatol 139 (1998) 834-839
8. Taylor B., Wadsworth J., Wadsworth M., and Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 2 (1984) 1255-1257
9. Leung D.Y., and Bieber T. Atopic dermatitis. Lancet 361 (2003) 151-160
10. Larsen F.S., and Hanifin J.M. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 22 (2002) 1-24
11. Spergel J.M., and Paller A.S. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 112 Suppl 6 (2003) S118-S127
12. Eichenfield L.F., Hanifin J.M., Luger T.A., et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 49 (2003) 1088-1095
13. Breuer K., Werfel T., and Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 6 (2005) 65-77
14. Ahuja A., Land K., and Barnes C.J. Atopic dermatitis. South Med J 96 (2003) 1068-1072
15. Wollenberg A., Kraft S., Oppel T., and Bieber T. Atopic dermatitis: Pathogenetic mechanisms. Clin Exp Dermatol 25 (2000) 530-534
16. Sampson H.A. Food allergy. Part 1: Immunopathogenesis and clinical disorders. J Allergy Clin Immunol 103 (1999) 717-728
17. Wheatley L.M., and Platts-Mills T.A.E. The role of inhalant allergens in atopic dermatitis. In: Leung D.Y.M., and Greaves M.W. (Eds). Allergic Skin Disease: A Multidisciplinary Approach (2000), Marcel Dekker, New York, NY 423-434
18. Chang J., and Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm 11 (2005) 66-73
19. Hebert A.A., Warken K.A., and Cherill R. Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg 20 (2001) 260-267
20. Hanifin J.M., and Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Suppl 92 (1980) 44-47
21. Leung D.Y., Nicklas R.A., Li J.T., et al., Joint Task Force on Practice Parameters. Disease management of atopic dermatitis: An updated practice parameter. Ann Allergy Asthma Immunol 93 Suppl 2 (2004) S1-S21
22. [published correction appears in J Am Acad Dermatol. 2005;52:156]. Hanifin J.M., Cooper K.D., Ho V.C., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol 50 (2004) 391-404
23. Eichenfield L.F. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy 59 Suppl 78 (2004) 86-92
24. vi-vii. Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin North Am 24 (2004) 631-644
25. Hengge U.R., Ruzicka T., Schwartz R.A., and Cork M.J. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54 (2006) 1-15
26. Feldmann R.J., and Maibach H.I. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 48 (1967) 181-183
27. [published correction appears in Dermatology. 2005;211:292]. Hultsch T., Kapp A., and Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211 (2005) 174-187
28. Grassberger M., Baumruker T., Enz A., et al. A novel antiinflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 141 (1999) 264-273
29. Stuetz A., Grassberger M., and Meingassner J.G. Pimecrolimus (Elidel, SDZ ASM 981)-preclinical pharmacology profile and skin selectivity. Semin Cutan Med Surg 20 (2001) 233-241
30. Dworzak M.N., Froschl G., Printz D., et al. Skin-associated lymphocytes in the peripheral blood of patients with atopic dermatitis: Signs of subset expansion and stimulation. J Allergy Clin Immunol 103 (1999) 901-906
31. Zuberbier T., Chong S.U., Grunow K., et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 108 (2001) 275-280
32. Hoetzenecker W., Ecker R., Kopp T., et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 115 (2005) 1276-1283
33. Meurer M., Fartasch M., Albrecht G., et al., CASM-DE-01 Study Group. Long-term efficacy and safe ty of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 208 (2004) 365-372
34. Eichenfield L.F., Lucky A.W., Boguniewicz M., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 46 (2002) 495-504
35. Wahn U., Bos J.D., Goodfield M., et al., Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110 (2002) e2
36. Topical therapy. In: Champion R.H., Burton J.L., and Ebling F.G.P. (Eds). Textbook of Dermatology. 5th ed (1992), Blackwell Scientific, Oxford, UK 3072-3076
37. Queille-Roussel C., Paul C., Duteil L., et al. The new topical ascomycin derivative SDZ ASM 981 does not in duce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Br J Dermatol 144 (2001) 507-513
38. Moore D.E. Drug-induced cutaneous photosensitivity: Incidence, mechanism, prevention and management. Drug Saf 25 (2002) 345-372
39. Leung D.Y. Infection in atopic dermatitis. Curr Opin Pediatr 15 (2003) 399-404
40. Billich A., Aschauer H., Aszodi A., and Stuetz A. Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 269 (2004) 29-35
41. Van Leent E.J., Ebelin M.E., Burtin P., et al. Low systemic exposure after repeated topical application of pime crolimus (Elidel), SD Z ASM 981 in patients with atopic dermatitis. Dermatology 204 (2002) 63-68
42. Harper J., Green A., Scott G., et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 144 (2001) 781-787
43. Allen B.R., Lakhanpaul M., Morris A., et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1 % in atopic dermatitis patients. Arch Dis Child 88 (2003) 969-973
44. Thaci D., Steinmeyer K., Ebelin M.E., et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 207 (2003) 37-42